The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Eris Lifesciences has partnered with Natco Pharma to bring semaglutide, a key GLP-1 receptor agonist, to the Indian market for Type 2 diabetes management. With CDSCO approval secured, the launch is set for March 2026. This move strengthens Eris's diabetes portfolio amid rising diabetes cases in India.
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
Novo Nordisk faces an investor investigation by DJS Law Group over claims of misleading statements about its CagriSema weight loss drug trial. The phase 3 study failed to demonstrate non-inferiority against Eli Lilly's tirzepatide after 84 weeks, triggering a sharp 15%+ premarket stock plunge on February 23, 2026. Investors affected by the drop may have rights under securities laws.
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
Katy Perry's noticeable weight loss transformation starting in 2023 has fans speculating about Ozempic use, even as she credits diet and hydration. Online chatter about 'Ozempic face' intensified after her 2024 performances and social media posts. Despite denials from Perry and sources, rumors persist into 2025.
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
